Arpeggio Biosciences, a preclinical therapeutics company whose technology targets transcriptional dysregulation in disease, and Builders VC, announced a $17 million dollar Series A funding round, following a $3.2 million dollar seed round completed in 2020. Funding was led by Builders VC.

This Series A funding was also supported by Arpeggio's seed round investors: Khosla Ventures, TechU Ventures, FundersClub, Alice Zhang, and Fifty Years, with new participation from Tencent, ATEM Capital, Formic Ventures, Tau Ventures, Milad Alucozai (BoxOne Ventures), and Matthew De Silva (Longtail Capital).

Arpeggio's technology combines a proprietary biological assay and machine learning algorithms that, together, enable rapid, high-resolution snapshots of cellular dynamics following drug treatment. These snapshots are then analyzed to reveal the biological networks that determine a drug's function and guide therapeutic development.